A weekly fractionation of EPIRUBICIN at an unchanged dose intensity leads to a significant decrease in toxicity. 2. The weekly administration of 25 mg/m2 EPIRUBICIN is effective in treating hormone refractory prostate carcinoma and completely fulfills the requirements for palliation.